Reporting and Representativeness of Race, Ethnicity, and Socioeconomic Status in Systemic Sclerosis Randomized Trials: An Observational Study.
Journal
Arthritis care & research
ISSN: 2151-4658
Titre abrégé: Arthritis Care Res (Hoboken)
Pays: United States
ID NLM: 101518086
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
07
10
2022
received:
29
06
2022
accepted:
08
11
2022
medline:
28
7
2023
pubmed:
12
11
2022
entrez:
11
11
2022
Statut:
ppublish
Résumé
To assess how and to what extent socioeconomic status and ethnicity/race of participants are reported in randomized controlled trials (RCTs) on systemic sclerosis (SSc), and to estimate the representativeness of different ethnic/racial groups in SSc RCTs. We searched all published RCTs on SSc indexed in PubMed. We retrieved information on main features of RCTs published from 2000 onward and recorded for each study whether race/ethnicity was reported; how ethnicity/race was defined and assigned; and the number of patients included for each racial/ethnic group. Multivariable logistic regression was used to identify factors associated with race/ethnicity reporting. Proportion of races/ethnicities included in US-based RCTs on SSc was examined and compared with US demographic data. We included 106 studies, mostly conducted in Europe (42%) or North America (25%), published after 2010 (74%), and enrolling a total of 6,693 patients. About one-third of studies provided information about race/ethnicity, with no improved reporting over time. Only 2 papers reported patient's socioeconomic status. Study location (US or intercontinental) was the only significant factor associated with a better reporting of race/ethnicity in multivariable analysis. In studies where race/ethnicity was reported, White patients were mostly represented (79%), followed by Asian (7%), and African American (6%). In the sensitivity analysis limited to studies from the US, underrepresentation of African American patients was observed in the 2000-2010 time period, but not later. Documentation of race/ethnicity and socioeconomic status is poor in RCTs on SSc. More effort should be made to document race/ethnicity and socioeconomic status and to promote diversity in SSc RCTs.
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1698-1705Informations de copyright
© 2022 American College of Rheumatology.
Références
Baker EH. The Wiley Blackwell encyclopedia of health, illness, behavior, and society. New York (NY): John Wiley & Sons; 2014. p. 2210-14.
Clark LT, Watkins L, Piña IL, et al. Increasing diversity in clinical trials: overcoming critical barriers. Curr Probl Cardiol 2019;44:148-72.
Glickman SW, McHutchison JG, Peterson ED, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009;360:816-23.
Knepper TC, McLeod HL. When will clinical trials finally reflect diversity? Nature 2018;557:157-9.
Ramamoorthy A, Pacanowski MA, Bull J, et al. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther 2015;97:263-73.
Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
Aguirre A, Izadi Z, Trupin L, et al. Race, ethnicity, and disparities in risk of end-organ lupus manifestations following a systemic lupus erythematosus diagnosis in a multiethnic cohort. Arthritis Care Res (Hoboken) 2023;75:34-43.
Moore DF, Steen VD. Racial disparities in systemic sclerosis. Rheum Dis Clin North Am 2020;46:705-12.
Al-Sheikh H, Ahmad Z, Johnson SR. Ethnic variations in systemic sclerosis disease manifestations, internal organ involvement, and mortality. J Rheumatol 2019;46:1103-8.
Arnett FC, Howard RF, Tan F, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma: association with an Amerindian HLA haplotype. Arthritis Rheum 1996;39:1362-70.
Jaeger VK, Tikly M, Xu D, et al. Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology (Oxford) 2020;59:1684-94.
Ng SA, Low AH. Systemic sclerosis in Asians: are there racial differences? J Scleroderma Relat Disord 2022;7:98-109.
Li X, Qian YQ, Liu N, et al. Survival rate, causes of death, and risk factors in systemic sclerosis: a large cohort study. Clin Rheumatol 2018;37:3051-6.
Wangkaew S, Prasertwitayakij N, Phrommintikul A, et al. Causes of death, survival and risk factors of mortality in Thai patients with early systemic sclerosis: inception cohort study. Rheumatol Int 2017;37:2087-94.
Moon KW, Lee SS, Lee YJ, et al. Clinical and laboratory characteristics and mortality in Korean patients with systemic sclerosis: a nationwide multicenter retrospective cohort study. J Rheumatol 2018;45:1281-8.
Poormoghim H, Andalib E, Jalali A, et al. Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran. Rheumatol Int 2016;36:925-34.
Iudici M, Jarlborg M, Lauper K, et al. Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database. Rheumatology (Oxford) 2022;61:743-55.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W64.
Glanville JM, Lefebvre C, Miles JN, et al. How to identify randomized controlled trials in MEDLINE: ten years on. J Med Libr Assoc 2006;94:130-6.
Clarivate. Journal citation reports. URL: https://clarivate.com/webofsciencegroup/solutions/journal-citation-reports/?gclid=Cj0KCQjwwJuVBhCAARIsAOPwGAS66fP0sWCYWEHKsWv1vYfHO7ph-Vnx4kzi-yqp-WcAb5pOqOxl7joaAiTfEALw_wcB.
Kane RL, Wang J, Garrard J. Reporting in randomized clinical trials improved after adoption of the CONSORT statement. J Clin Epidemiol 2007;60:241-9.
Hopewell S, Dutton S, Yu LM, et al. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ 2010;340:c723.
Saginur M, Fergusson D, Zhang T, et al. Journal impact factor, trial effect size, and methodological quality appear scantly related: a systematic review and meta-analysis. Syst Rev 2020;9:53.
Sheikh A, Netuveli G, Kai J, et al. Comparison of reporting of ethnicity in US and European randomised controlled trials. BMJ 2004;329:87-8.
Turner BE, Steinberg JR, Weeks BT, et al. Race/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am 2022;11:100252.
US Census Bureau. National intercensal tables: 2000-2010. URL: https://www.census.gov/data/tables/time-series/demo/popest/intercensal-2000-2010-national.html.
US Census Bureau. National population by characteristics: 2010-2019. URL: https://www.census.gov/data/datasets/time-series/demo/popest/2010s-national-detail.html.
Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.
Ramamoorthy A, Kim HH, Shah-Williams E, et al. Racial and ethnic differences in drug disposition and response: review of new molecular entities approved between 2014 and 2019. J Clin Pharmacol 2022;62:486-93.
Bierer BE, White SA, Meloney LG, et al. Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard (MRCT Center). Achieving diversity, inclusion, and equity in clinical research guidance document. Version 1.2. 2021. URL: https://mrctcenter.org/diversity-in-clinical-research/wp-content/uploads/sites/11/2021/09/MRCT-Center-Diversity-Guidance-Document-Version-1.2.pdf.
Strait A, Castillo F, Choden S, et al. Demographic characteristics of participants in rheumatoid arthritis randomized clinical trials: a systematic review. JAMA Netw Open 2019;2:e1914745.
Falasinnu T, Chaichian Y, Bass MB, et al. The representation of gender and race/ethnic groups in randomized clinical trials of individuals with systemic lupus erythematosus. Curr Rheumatol Rep 2018;20:20.
National Institutes of Health. Amendment: NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research. URL: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-014.html.
Food and Drug Administration. Clinical trial diversity. URL: https://www.fda.gov/consumers/minority-health-and-health-equity/clinical-trial-diversity.
Simon P. Collecting ethnic statistics in Europe: a review. Ethn Racial Stud 2012;35:1366-91.
Ringelheim J, De Schutter O. Ethnic monitoring. The processing of racial and ethnic data in anti-discrimination policies: reconciling the promotion of equality with privacy rights. Brussels: Bruylant; 2010.
Sharrocks K, Spicer J, Camidge DR, et al. The impact of socioeconomic status on access to cancer clinical trials. Br J Cancer 2014;111:1684-7.
Astrike-Davis EM, Cleveland RJ, Bridges SL Jr, et al. Associations of socioeconomic status with disease progression in African Americans with early rheumatoid arthritis. Arthritis Care Res (Hoboken) 2023;75:85-91.
Moore DF, Kramer E, Eltaraboulsi R, et al. Increased morbidity and mortality of scleroderma in African Americans compared to Non-African Americans. Arthritis Care Res (Hoboken) 2019;71:1154-63.
Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010;63:834-40.
George S, Duran N, Norris K. A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am J Public Health 2014;104:e16-31.
Food and Drug Administration. Collection of race and ethnicity data in clinical trials. 2016. URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collection-race-and-ethnicity-data-clinical-trials.
Flanagin A, Frey T, Christiansen SL. Updated guidance on the reporting of race and ethnicity in medical and science journals. JAMA 2021;326:621-7.
International Committee of Medical Journal Editors. Recommendations. 2022. URL: https://www.icmje.org/recommendations/.